Aurobindo Pharma Stock Rises on Production Restart

  Published 11 months ago

Shares of India's Aurobindo Pharma rise 2.4% as Lyfius Pharma restarts Kakinada production, despite a 15% YTD drop.

  • Restarting Kakinada facility boosts shares; analysts rate stock 'buy' with 1370 rupees median target.
  • Stock up 2.4% on production resumption despite year, to, date decline of about 15%.
  • LSEG data shows a positive outlook for Aurobindo Pharma amid operational recovery.

You might like these

TVS Supply Chain Profit Soars 914%

Marathon Nextgen Realty Raises Rs.900 Crore via QIP

Five-Star Finance Slides on Asset Woes

NLC India KABIL Pursue Critical Minerals

Tejas Networks Soars on ₹1525 Crore BSNL 4G Order

Suzuki Invests $8B, Launches India EV Hub

Reliance Stock Rises on Strong Q1 Outlook, Jio IPO Hopes

News that matters the most ⚡